Abstract:BACKGROUND: Bladder cancer (BLCA) is the most prevalent tumor affecting the urinary system, and has contributed to a rise in morbidity and mortality rates. Herein, we sought to identify the methylation-driven genes (MDGs)of BLCA in an effort to develop prognostic biomarkers suitable for the individualized assessment of patients with this particular cancer.METHODS: The Cancer Genome Atlas (TCGA) dataset was distributed into training set (n=272) and testing set(n=117). The ConsensusClusterPluspackage was used to identify BLCA subtypes. The ChAMP package was used to analyze differential methylation probe (DMP) and differential methylation region (DMR). The differentially expressed genes (DEGs) were detected using DESeq2. Gene Ontology (GO) term enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were utilized to identify the pathways enriched of DEGs. Correlation analysis between 5'-C-phosphate-G-3's (CpGs) and DEGs was employed to identify the MDGs. The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) was used to build the protein-protein interaction (PPI) network of MDGs. Screening for BLCA prognosis-related MDGs and clinical features was conducted via the Cox regression model. A prognosis-related nomogram was developed and validated for prediction of the BLCA patients' survival.RESULTS: We identified 2 BLCA clusters. Differential methylations at CpGs sites (dm-CpGs) were observed between cluster2 and cluster1, with 14,189 of them hypermethylated and 878 hypomethylated, predominantly in the CpG islands. In addition, a total 4,234 DEGs were identified between cluster2 and cluster1. The KEGG pathway and GO term enrichment analyses found that some DEGs were significantly enriched in multiple cancer-related pathways. A total of 33 MDGs were detected from correlation analysis between CpGs and DEGs. We selected BLCA-specific prognostic DMGs signatures for risk model development. The nomogram comprised a risk model to predict survival for BLCA patients. The efficiency of the prognostic prediction model was validated in the training and testing set.CONCLUSIONS: This study discovered differential methylation patterns and MDGs in BLCA patients, which provided a bioinformatics basis for guiding BLCA early diagnosis and prognosis analyses.

High-Resolution Melting Analysis of BLU Methylation Levels in Gastric, Colorectal, and Pancreatic Cancers

Inactivation Of Blu Is Associated With Methylation Of Sp1-Binding Site Of Blu Promoter In Gastric Cancer

High-resolution melting analysis of PCDH10 methylation levels in gastric, colorectal and pancreatic cancers.

Semi-quantitative detection of GADD45-gamma methylation levels in gastric, colorectal and pancreatic cancers using methylation-sensitive high-resolution melting analysis

High-resolution melting analysis of ADAMTS9 methylation levels in gastric, colorectal, and pancreatic cancers.

High-resolution melting analysis of ADAMTS18 methylation levels in gastric, colorectal and pancreatic cancers

Identification of potential DNA methylation biomarkers related to diagnosis in patients with bladder cancer through integrated bioinformatic analysis

Genome-wide Analysis of Aberrant DNA Methylation for Identification of Potential Biomarkers in Colorectal Cancer Patients.

Altered 5-Hydroxymethylcytosine Landscape in Primary Gastric Adenocarcinoma

Combined Detection of Plasma ZIC1, HOXD10 and RUNX3 Methylation is a Promising Strategy for Early Detection of Gastric Cancer and Precancerous Lesions.

Tumor Suppressor Gene BLU is Frequently Downregulated by Promoter Hypermethylation in Myelodysplastic Syndrome

Analysis of DNA Methylation Patterns Associated with the Gastric Cancer Genome.

Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast and Gastric Cancer Patients

Bioinformatics analysis to screen DNA methylation-driven genes for prognosis of patients with bladder cancer

Genome-wide DNA methylation profiling reveals a novel hypermethylated biomarker PRKCB in gastric cancer

Hypermethylated DNA as potential biomarkers for gastric cancer diagnosis.

Prognostic Value Of Differentially Methylated Gene Profiles In Bladder Cancer

Silencing-specific Methylation and Single Nucleotide Polymorphism of Hmlh1 Promoter in Gastric Carcinomas.

Association of BLCA-4 Hypomethylation in Blood Leukocyte DNA and the Risk of Bladder Cancer in a Chinese Population

Identification of Prognostic Biomarkers for Bladder Cancer Based on DNA Methylation Profile

Exploring prognostic DNA methylation genes in bladder cancer: a comprehensive analysis